Imugene and RenovoRx Join Forces for Oncolytic Virus Therapy

Imugene (ASX: IMU) and RenovoRx have joined forces in a strategic research collaboration to optimize the delivery of Imugene's CF33 oncolytic virus therapy using RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform. The collaboration aims to target difficult-to-access tumors, such as pancreatic and liver cancers, by delivering the oncolytic virus through the TAMP system. This approach may overcome limitations seen in traditional administration methods, where dense fibrous tissue and inadequate blood vessel supply hinder therapy uptake.

The TAMP platform ensures precise therapeutic delivery to the targeted tissue. Previous studies have demonstrated a significant increase in local tissue concentration using TAMP compared to conventional IV delivery, offering potential improvements in efficacy and safety for cancer patients. The initial collaboration will be funded from existing budgets and resources for up to four months, with the intention to expand the partnership further upon successful results. Both companies are hopeful that this joint effort will lead to more effective treatment options for patients with difficult-to-access tumors and advance the field of immunotherapy for metastatic diseases.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com